02157.HK

Research · Aug 25, 2026

CLDN18.2-Targeted Cancer Therapy Broadens First-Line Population by Dropping Staining Cutoff

NovaBridge says the FDA's first-line population for givastomig requires only CLDN18.2 positivity, with no staining cutoff, and sizes it at 105,000 patients.